YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC

Funding Rounds

▤ Summary

YolTech Therapeutics closed about $45 million in Series B financing led by the AstraZeneca-CICC healthcare investment fund. The company will use the capital to advance its clinical programs and global strategy. YolTech develops in vivo gene-editing therapies built on proprietary CRISPR nucleases, base editors, and lipid nanoparticle delivery systems. It has already moved multiple programs into clinical development and has manufacturing capability to support later-stage and early commercial scale-up.

$ Funding

$
Amount $45.0M Total raised
□
Date September 11, 2025 Announcement date
◎
Investors - Lead investors
▥
Company - Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies